| 非经营性资金 | | 占用方与上 | 上市公司核 | 2023 年期初占 | 2023 年上半年 占用累计发生 | 2023 年上半 | 2023 年上半 | 2023 年上半年 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | 用资金余额 | 金额（不含利 | 年占用资金 | 年偿还累计发 | 末占用资金余 | 因 | | | | | 联关系 | 目 | | 息） | 的利息(如有) | 生金额 | 额 | | | | 控股股东、实 际控制人及其 | | | | | | | | | | 非经营性占 | | 附属企业 | | | | | | | | | | 用 | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、 实际控制人及 | | | | | | | | | | 非经营性占 | | 其附属企业 | | | | | | | | | | 用 | | 小计 | - | - | - | ...

朗姿股份有限公司独立董事 关于控股股东及其他关联方占用公司资金、公司对外担保情况 的专项说明和独立意见 根据《上市公司监管指引第8号——上市公司资金往来、对外担保的监管要 求》《深圳证券交易所股票上市规则》《上市公司自律监管指引第1号——主板 上市公司规范运作》等相关规定，作为公司的独立董事，我们对公司2023年半年 度控股股东及其他关联方占用公司资金、公司对外担保情况进行了认真核查，出 具专项报告并发表独立意见： 一、关于公司2023年半年度控股股东及其他关联方占用资金情况的独立意 见 报告期内公司不存在控股股东及其关联方占用上市公司资金的情况。 二、关于公司2023年半年度对外担保情况的独立意见 报告期内，公司所进行的担保均为全资子公司提供的担保或全资子公司为公 司提供的担保，公司及子公司未发生对外担保情况。公司为子公司提供担保，主 要是为支持子公司的经营和长期发展需要，符合全体股东的利益，公司对子公司 的担保风险可控。 公司董事会、股东大会已履行了必要的审批程序，表决程序合法、有效；不 存在损害中小股东利益的情形。 独立董事：朱友干、陈丽京 2023 年 8 月 29 日 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2023-068 朗姿股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、朗姿股份有限公司（以下简称"朗姿股份"或"公司"） 第五届董事会 第三次会议和 2022 年度股东大会分别审议通过了《关于 2023 年度对外担保额度 的议案》，同意 2023 年度公司及其控股子公司的对外担保总额不超过 40.6 亿元 （以下除非特别注明，所称"元"均指"人民币元"），其中对资产负债率未超 过 70%的控股子公司担保额度为 40 亿元，对资产负债率超过 70%的控股子公司 担保额度为 0.6 亿元。截止本公告披露日，公司及控股子公司对外担保总余额为 80,510 万元，占公司 2022 年度经审计净资产的 27.97%；其中，实际被担保方北 京莱茵服装有限公司资产负债率超过 70%，对资产负债率超过 70%的控股子公 司担保余额为 1,000 万元。 2、公司及控股子公司未对合并报表范围外的公司提供担保。 3、公司及控股子公司未发生逾期担保、涉及诉讼的担保及因 ...

关于投资设立医美创业投资基金博恒二号备案完成 暨进展公告 本公司及董事会全体人员保证公告信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、设立基金的基本情况 经朗姿股份有限公司（以下简称"公司"）分别于2023年6月16日召开的第五 届董事会第七次会议和2023年7月7日召开的2023年第二次临时股东大会审议通 过，同意公司与参股公司北京朗姿韩亚资产管理有限公司（以下简称"韩亚资管"） 及公司控股股东、实际控制人申东日先生签订附生效条件的《芜湖博恒二号创业 投资合伙企业（有限合伙）合伙协议》（以下简称《有限合伙协议》或"本协议"）。 公司以自有资金3,800万元人民币，作为有限合伙人出资设立医美创业投资基金 —芜湖博恒二号创业投资合伙企业（有限合伙）（以下简称 "博恒二号"）， 朗姿韩亚资管为博恒二号的普通合伙人也即基金管理人。本次投资事项的具体信 息详见公司在巨潮资讯网（www.cninfo.com.cn）、《证券时报》和《上海证券报》 发布的《朗姿股份有限公司关于投资设立医美创业投资基金博恒二号暨关联交易 的公告》（编号：2023-046）。 二、基金备案完成情况 证券代码：0 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,139,399,566.72, representing a 21.31% increase compared to ¥939,226,348.80 in the same period last year[13] - Net profit attributable to shareholders was ¥62,049,136.05, a significant increase of 6985.13% from a loss of ¥901,205.40 in the previous year[13] - The net cash flow from operating activities was ¥221,827,689.62, up 166.78% from ¥83,149,801.78 in the same period last year[13] - Basic and diluted earnings per share were both ¥0.1402, a substantial increase of 2849.02% from -¥0.0051 in the previous year[13] - The company achieved a 30.68% increase in revenue from its medical beauty business, totaling ¥45,904.01 million[13] - Operating profit for the current period was ¥67,084,783.35, a substantial increase of 667.03% from a loss of ¥11,830,946.94 in the previous year[32] - Total revenue for the first quarter reached ¥1,139,399,566.72, an increase of 21.3% compared to ¥939,226,348.80 in the same period last year[44] - The company's net profit attributable to shareholders was not explicitly stated, but the retained earnings increased to ¥819,529,704.42 from ¥757,480,568.37, indicating a growth of 8.2%[43] - The net profit for the period was $57.26 million, compared to a net loss of $8.39 million in the same period last year[49] - Earnings per share (EPS) for the current period was $0.1402, a recovery from a loss of $0.0051 per share in the previous year[49] Cash Flow and Investments - The net cash flow from financing activities was -$63.77 million, compared to -$223.94 million in the previous period, indicating an improvement[48] - The net increase in cash and cash equivalents was $51.67 million, contrasting with a decrease of $90.89 million in the prior period[48] - Operating cash flow generated was $221.83 million, a significant increase from $83.15 million year-over-year[51] - The total cash inflow from operating activities was $1.18 billion, compared to $1.06 billion in the previous year, showing a growth of about 10.8%[51] - Cash outflows from investing activities totaled $120.51 million, a decrease from $358.62 million in the prior year, indicating reduced investment expenditures[51] - The company reported a net investment income of ¥30,845,384.18, significantly higher than ¥10,955,085.73 from the previous year, marking an increase of 181.5%[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,052,712,529.26, reflecting a slight decrease of 0.81% from ¥7,110,249,238.41 at the end of the previous year[23] - The total liabilities increased to ¥3,417,115,780.85 from ¥3,492,390,072.87, a decrease of 2.1%[43] - Long-term borrowings increased to ¥70,000,000.00, marking a 100% increase due to new long-term loans taken during the period[17] - The company's trading financial assets increased by 273.94% to ¥20,652,672.95, up from ¥5,523,031.04 at the end of the previous year[17] - The total assets of the company were ¥7,052,712,529.26, down from ¥7,110,249,238.41, indicating a decrease of 0.8%[43] Shareholder Information - The company reported a total of 69,396 common shareholders at the end of the reporting period, with the largest shareholder holding 47.82% of the shares[24] - Shareholders' equity attributable to the parent company was ¥2,927,047,166.38, a 1.69% decrease from ¥2,878,340,308.08 at the end of the previous year[23] Expenses and Costs - Total operating costs amounted to ¥1,078,495,518.34, up from ¥933,074,035.42, reflecting a rise of 15.6% year-over-year[44] - Research and development expenses for the quarter were ¥23,045,991.84, down from ¥29,054,299.01, a decrease of 20.7%[44] - The company reported a 31.00% increase in payable employee compensation, totaling ¥43,348,585.08, due to increased performance incentives related to the growth in medical beauty business revenue[17]

LANCY 2023年4月 (19) (8) (8) 1 第一节 重要提示、目录和释义 公司负责人申东日、主管会计工作负责人常静及会计机构负责人(会计主 管人员)蒋琼声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司需遵守《深圳证券交易所上市公司自律监管指引第 3 号——行业信 息披露》中纺织服装相关业的披露要求 业"。 朗姿股份有限公司 2022 年年度报告全文 朗姿股份有限公司 2022 年年度报告全文 2、载有会计师事务所盖章、注册会计师签名并盖章的审计报告原件； 朗姿股份有限公司 2022 年年度报告全文 4 5 6 | --- | --- | --- | --- | |-----------------------------|---------------------------|-----------------------------|------------------| | 股票简称 | 朗姿股份 | 股票代码 | 002612 | | 变更前的股票简称（如有） | 无 | | | | 股票上市证券交易所 | 深圳证券交易所 | | | | ...

证券代码：002612 证券简称：朗姿股份 朗姿股份有限公司投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |------------------------------|-------------------------------------|------------------------------------------------------------| | | | | | 投 资 者 关 | ■ 特定对象调研 | □分析师会议 | | 系 活 动 类 | □ | 媒体采访 □业绩说明会 | | 别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 | 国泰君安：刘越男、赵政 | | | 名 称 及 人 | 民生加银：蔡晓 | | | 员姓名 | 亚太财产：陈光 | | | 时间 | 2020 年 11 月 3 | 日上午 10:00 ； | | 地点 | 朗姿大厦 16 | 层会议室 | | | | | | 上 市 公 司 接 待 人 员 姓名 | 董事会秘书：王 ...

朗姿股份有限公司 2022 年第三季度报告 证券代码：002612 证券简称：朗姿股份 公告编号：2022-064 朗姿股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 1 朗姿股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|--------------------|-------------------------- ...

Financial Performance - The company reported a revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[1] - The company's operating revenue for the reporting period was approximately ¥1.81 billion, representing a 1.10% increase compared to the same period last year[25] - The company achieved a total operating revenue of 1,809.13 million yuan in the first half of 2022, representing a year-on-year increase of 1.10%[35] - The net profit attributable to shareholders of the listed company was approximately ¥9.25 million, a decrease of 90.09% year-on-year[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥13.08 million, down 85.10% from the previous year[25] - The net cash flow from operating activities was approximately ¥107.07 million, a decline of 50.14% compared to the same period last year[25] - The total assets at the end of the reporting period were approximately ¥6.70 billion, a decrease of 2.26% from the end of the previous year[25] - The net assets attributable to shareholders of the listed company were approximately ¥2.94 billion, down 0.66% from the previous year[25] - The basic earnings per share were ¥0.0209, reflecting a 90.09% decrease year-on-year[25] - The diluted earnings per share were also ¥0.0209, showing a 90.09% decline compared to the same period last year[25] - The weighted average return on net assets was 0.31%, down 2.81% from the previous year[25] Market Expansion and Strategy - The company plans to expand its market presence by opening 30 new retail locations by the end of 2023[3] - The company is exploring potential acquisitions in the fashion industry to enhance its product offerings[7] - A strategic partnership with a leading technology firm aims to improve online sales channels, targeting a 25% increase in e-commerce revenue[8] - The company aims to innovate through product and service enhancements to create value for customers, maintaining a commitment to quality and brand reputation[35] - The company is focusing on expanding its medical beauty business through the growth of self-built hospital-level institutions and increasing the scale of its chain operations[71] - The company aims to enhance its domestic infant clothing market share by promoting the ETTOI brand and leveraging local designers[80] - The company is focusing on expanding cooperation with external investment institutions and industry funds to enhance its capital market presence[163] Product and Service Development - New product launches in the fashion segment contributed to a 10% increase in sales volume compared to the previous year[4] - The company has invested 200 million RMB in R&D for new technologies in medical beauty treatments[5] - The company has optimized its product development process using a self-developed PLM system, improving accuracy and efficiency in product design[55] - The company launched the "Seedling Doctor Training Program" in 2022 to systematically train qualified medical personnel through various educational methods[70] - The company has established three major medical beauty brands: Milan Baiyu, Jingfu Medical Beauty, and Gao Yisheng, each targeting different market segments[62][65][66] Operational Efficiency and Management - The company has optimized its organizational structure by establishing regional divisions to improve management efficiency and resource integration[70] - The company is enhancing management efficiency through refined management practices and increasing the proportion of online business to mitigate rising labor costs[156] - The company is leveraging shared resources among its medical beauty brands to enhance competitiveness and optimize procurement and marketing strategies[160] - The company is enhancing its operational efficiency and profitability through innovative business models and improved management capabilities, aiming to increase its financing credibility and bank credit scale[163] Customer Engagement and Sales Channels - The online sales channel for women's apparel reached nearly 200 million yuan, representing a year-on-year growth of approximately 20%[55] - The overall payment amount across all channels exceeded 650 million yuan, marking a 30% increase year-on-year, with Douyin channel payments soaring by 97%[56] - The company has established a marketing network with 603 offline sales terminals and 30 online channels for its women's clothing business[95] - The company has a loyal customer base, with over 319,300 offline VIP customers and approximately 349,000 online VIP customers in the women's clothing segment[95] Challenges and Risks - Risk management strategies have been outlined to address potential market fluctuations and operational challenges[10] - The company faces risks related to medical accidents and personnel turnover, with a focus on maintaining high standards in medical procedures and attracting talent through incentive policies[158] - The company is addressing rapid changes in consumer demand in the mid-to-high-end women's clothing market by improving design innovation and maintaining a multi-brand strategy[160] Financial Commitments and Governance - The company has committed to providing at least RMB 500 million to support its medical beauty business strategy within two years following the completion of a share reduction plan[196] - The controlling shareholders have pledged not to transfer more than 25% of their shares annually during their tenure[196] - The company has established strict principles for related party transactions to ensure fairness and compliance with legal regulations[196] - The company has committed to adhering to the latest regulatory opinions regarding the lock-up period and related party transactions[191] Social Responsibility and Compliance - The company’s subsidiary, Langzi Medical, was awarded the "2022 Outstanding Corporate Social Responsibility" for its commitment to social responsibility and public welfare initiatives[186] - The company has not been penalized for environmental issues during the reporting period and actively collaborates with suppliers to build a green supply chain[185]

朗姿股份有限公司 2022 年第一季度报告全文 证券代码：002612 证券简称：朗姿股份 公告编号：2022-027 朗姿股份有限公司 2022 年第一季度报告 2022 年 04 月 1 朗姿股份有限公司 2022 年第一季度报告全文 朗姿股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------- ...